After grabbing 22619.0 shares, the institutional investor is now in possession of 22619.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.67% having worth around $3845.0. Moreover, The Vanguard Group, Inc. increased its share by 12455.0 to have a control over 12455.0 shares. And Bank of America, NA raised its holdings to 200.0 shares by acquiring 200.0 shares or 0.01% of the stake.
Kintara Therapeutics Inc (KTRA) concluded trading on Thursday at a closing price of $0.12, with 7.12 million shares of worth about $0.85 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -97.37% during that period and on Thursday, January 25 the price saw a gain of about 1.75%. Currently the company’s common shares owned by public are about 3.39M shares, out of which, 3.31M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 1 times over the past 12 months. They bought 59,800 shares in 1 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Fidelity Nasdaq Composite Index F, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Kintara Therapeutics Inc Fidelity Nasdaq Composite Index F is currently holding 30458.0 shares of worth totaling $5178.0. The company recently came buying 29240.0 shares which brought its stake up to 0.90% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 9104.0 shares, have now control over 0.27% of the stake in the company. It holds 0.0 shares of worth $1548.0.
Stock saw a price change of -16.08% in past 5 days and over the past one month there was a price change of -30.66%. Year-to-date (YTD), KTRA shares are showing a performance of -28.01% which decreased to -97.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.12 but also hit the highest price of $7.65 during that period. The average intraday trading volume for Kintara Therapeutics Inc shares is 5.69 million. The stock is currently trading -18.13% below its 20-day simple moving average (SMA20), while that difference is down -47.25% for SMA50 and it goes to -95.54% lower than SMA200.
Nantahala Capital Management LLC acquired 22619.0 shares of Kintara Therapeutics Inc having value of about $3845.0. Kintara Therapeutics Inc (NASDAQ: KTRA) currently have 3.39M outstanding shares and institutions hold larger chunk of about 2.89% of that. Holding of mutual funds in the company is about 1.79% while other institutional holders and individual stake holders have control over 2.08% and 0.50% of the stake respectively.
The stock has a current market capitalization of $0.41M and its 3Y-monthly beta is at 0.63. It has posted earnings per share of -$7.84 in the same period. It has Quick Ratio of 0.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KTRA, volatility over the week remained 9.38% while standing at 15.33% over the month.
Analysts are in expectations that Kintara Therapeutics Inc (KTRA) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is -$0.83 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$3.5 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 88.67% while it is estimated to increase by 21.43% in next year.
